On February 28, 2022, the thirteenth study site in our multi-site open-label extension study of MDMA-assisted therapy for PTSD (MAPPUSX) officially began screening potential study participants. This study site is taking place at Numinus Wellness in Vancouver, British Columbia, Canada. The MAPS Public Benefit Corporation (MAPS PBC) research team will conduct visits for informed consent forms (ICF) soon.
This study is a safety extension for Phase 3 participants who did not receive treatment due to the COVID-19 pandemic. The study will be conducted in up to 100 participants. Participants will receive a flexible dose of MDMA, followed by a supplemental dose (unless contraindicated) during the treatment period with manualized therapy in three monthly experimental sessions.